3.5 Cannabis, Hallucinogens, and Inhalants

Cannabis: impairment and a real withdrawal syndrome

Cannabis (THC) is the most-used illicit-or-legalized drug, and the exam's recurring theme is do not minimize it because of how common or legal it is. Intoxication brings relaxation, altered time perception, impaired attention and short-term memory, conjunctival injection (red eyes), increased appetite, and impaired driving. High doses — especially of concentrates and edibles — can trigger anxiety, panic, and transient paranoia.

The DSM-5 recognizes cannabis withdrawal as a genuine syndrome, contradicting the myth that cannabis causes no withdrawal. Symptoms appear within about a week of stopping heavy regular use:

Cannabinoid hyperemesis syndrome (CHS) is a high-yield, surprising fact: frequent (weekly or more), long-term (months or longer) cannabis use can cause recurrent severe nausea, vomiting, and abdominal pain, classically relieved by hot baths or showers. Symptoms usually remit within about two weeks of abstinence. A client with cyclic vomiting and compulsive hot showering who heavily uses cannabis should raise CHS — assess and refer medically rather than assuming an unrelated GI illness.

Hallucinogens, dissociatives, and club drugs

Classic hallucinogens (LSD, psilocybin mushrooms, mescaline) distort perception, mood, and thought; a frightening experience ("bad trip") brings panic, paranoia, and impaired judgment that can lead to unsafe behavior. There is generally no classic physical withdrawal, but acute psychological danger is real, and hallucinogen persisting perception disorder (HPPD) can cause later flashbacks.

Dissociatives are distinct and more dangerous behaviorally. PCP (phencyclidine) can cause violent agitation, marked analgesia (insensitivity to pain), nystagmus, and unpredictable aggression, making it a serious safety concern. Ketamine produces dissociation and, at high doses, a "K-hole." Stimulation should be minimized and safety prioritized.

Club drugs include MDMA (ecstasy/molly), which is part-stimulant, part-empathogen. Its dangerous medical risks are hyperthermia (overheating, which can cause organ failure) and hyponatremia (dangerously low sodium from drinking too much water while overheated). GHB is a CNS depressant with a narrow margin and dangerous withdrawal; flunitrazepam and GHB are associated with drug-facilitated assault.

The counseling skill during acute perceptual distress is not to argue the client out of a perception. Reduce stimulation, maintain safety, assess orientation and risk, and seek medical or crisis consultation if danger appears. A practical de-escalation approach often described as "talking down" uses a calm voice, reassurance that the experience is drug-related and will pass, and a low-stimulation environment — useful for a hallucinogen panic, but never a substitute for emergency care when a client is violent, suicidal, or medically unstable.

Inhalants, nicotine, and the anti-minimization rule

Inhalants (volatile solvents, aerosols, glue, paint thinner, nitrous oxide, alkyl nitrites) are exam favorites precisely because they are cheap, legal household products often used by adolescents — and easy to dismiss. The fact you must know is Sudden Sniffing Death Syndrome (SSDS): inhalants can sensitize the heart to adrenaline and trigger a fatal cardiac arrhythmia (cardiac arrest) — and it can happen on the very first use, in an otherwise healthy young person. Chronic use causes neurologic and organ damage.

The exam trap is treating inhalant use as harmless experimentation; the correct stance is urgent safety assessment of frequency, access, peer context, and need for referral.

Nicotine/tobacco is a stimulant with a defined withdrawal: irritability, anxiety, difficulty concentrating, increased appetite, restlessness, and craving. Onset is within hours; symptoms peak in 1-3 days and largely ease over 2-4 weeks, though cravings persist longer. Nicotine withdrawal is uncomfortable but not medically dangerous; it is still worth assessing because it affects engagement and relapse, and concurrent tobacco-cessation support is associated with better substance-use outcomes rather than threatening recovery.

Applied scenario: an adolescent is brought in after huffing aerosol at school and laughs it off as "not real drugs." The best CADC response is to assess acute medical safety, frequency, access, peer context, and family supervision, and refer — not to call it normal curiosity. A second scenario: an adult uses high-potency cannabis daily with panic attacks, poor sleep, and job problems; the strong answer screens for both substance-use and mental-health concerns and refers for mental-health evaluation without overstepping into diagnosis.

Exam traps: (1) assuming legality decides clinical importance — IC&RC competencies address use and addiction, not whether a jurisdiction permits possession; (2) minimizing inhalants; (3) arguing with a client during acute perceptual disturbance. Document what was used, route, amount, last use, observed behavior, reported effects, safety questions, and referrals — avoid vague phrases like "acted weird."

• Cannabis has a real DSM-5 withdrawal syndrome and can cause CHS.
• Hallucinogens risk panic; PCP risks violent agitation; MDMA risks hyperthermia.
• Inhalants can kill on first use via Sudden Sniffing Death Syndrome.
• Nicotine withdrawal peaks in 1-3 days and is uncomfortable but not lethal.